Phloretin and phlorizin promote lipolysis and inhibit inflammation in mouse 3T3-L1 cells and in macrophage-adipocyte co-cultures

Molecular Nutrition and Food Research

Volumn 57, Issue 10, 2013, Pages 1803-1813

  Huang, Wen Chung ^a   Chang, Wei Tien ^a   Wu, Shu Ju ^a   Xu, Pei Yin ^a   Ting, Nai Chun ^a   Liou, Chian Jiun ^a  

^a CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

3T3 L1; Lipolysis; Macrophage; Phloretin; Phlorizin

Indexed keywords

ANTIOBESITY AGENT; CHOLESTEROL ESTERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHLORETIN; PHLORIZIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

3T3 CELL LINE; 3T3-L1; ADIPOCYTE; ADIPOGENESIS; ANIMAL; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; COCULTURE; CYTOLOGY; DRUG EFFECT; INFLAMMATION; LIPOLYSIS; MACROPHAGE; METABOLISM; MOUSE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

3T3-L1; LIPOLYSIS; MACROPHAGE; PHLORETIN; PHLORIZIN;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-OBESITY AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; INFLAMMATION; LIPOLYSIS; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PHLORETIN; PHLORHIZIN; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEROL ESTERASE; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884919660     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300001     Document Type: Article

References (52)

1. Li, L., Wu, L. L., Adiponectin and interleukin-6 in inflammation-associated disease. Vitam. Horm. 2012, 90, 375-395.
2. Dietrich, M. O., Horvath, T. L., Limitations in antiobesity drug development: the critical role of hunger-promoting neurons. Nat. Rev. Drug Discov. 2012, 11, 675-691.
3. Romeo, G. R., Lee, J., Shoelson, S. E., Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1771-1776.
4. Lage, R., Dieguez, C., Vidal-Puig, A., Lopez, M., AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol. Med. 2008, 14, 539-549.
5. Towler, M. C., Hardie, D. G., AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 2007, 100, 328-341.
6. Lim, C. T., Kola, B., Korbonits, M., AMPK as a mediator of hormonal signalling. J. Mol. Endocrinol. 2010, 44, 87-97.
7. Liu, Q., Siloto, R. M., Lehner, R., Stone, S. J. et al., Acyl-CoA: diacylglycerol acyltransferase: molecular biology, biochemistry and biotechnology. Prog. Lipid Res. 2012, 51, 350-377.
8. Zechner, R., Zimmermann, R., Eichmann, T. O., Kohlwein, S. D. et al., FAT SIGNALS-lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012, 15, 279-291.
9. Gustafson, B., Adipose tissue, inflammation and atherosclerosis. J. Atheroscler. Thromb. 2010, 17, 332-341.
10. Smith, M. M., Minson, C. T., Obesity and adipokines: effects on sympathetic overactivity. J. Physiol. 2012, 590, 1787-1801.
11. Olefsky, J. M., Glass, C. K., Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72, 219-246.
12. Sun, K., Kusminski, C. M., Scherer, P. E., Adipose tissue remodeling and obesity. J. Clin. Invest. 2011, 121, 2094-2101.
13. Gershell, L., Type 2 diabetes market. Nat. Rev. Drug Discov. 2005, 4, 367-368.
14. Inkster, B., Zammitt, N. N., Frier, B. M., Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin. Drug Saf. 2012, 11, 597-614.
15. Scheen, A. J., Metformin + saxagliptin for type 2 diabetes. Expert Opin. Pharmacother. 2012, 13, 139-146.
16. Ehrenkranz, J. R., Lewis, N. G., Kahn, C. R., Roth, J., Phlorizin: a review. Diabetes Metab. Res. Rev. 2005, 21, 31-38.
17. Gosch, C., Halbwirth, H., Stich, K., Phloridzin: biosynthesis, distribution and physiological relevance in plants. Phytochemistry 2010, 71, 838-843.
18. Rezk, B. M., Haenen, G. R., van der Vijgh, W. J., Bast, A., The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids. Biochem. Biophys. Res. Commun. 2002, 295, 9-13.
19. Chang, W. T., Huang, W. C., Liou, C. J., Evaluation of the anti-inflammatory effects of phloretin and phlorizin in lipopolysaccharide-stimulated mouse macrophages. Food Chem. 2012, 134, 972-979.
20. Lotito, S. B., Frei, B., Relevance of apple polyphenols as antioxidants in human plasma: contrasting in vitro and in vivo effects. Free Radic. Biol. Med. 2004, 36, 201-211.
21. Hassan, M., El Yazidi, C., Landrier, J. F., Lairon, D. et al., Phloretin enhances adipocyte differentiation and adiponectin expression in 3T3-L1 cells. Biochem. Biophys. Res. Commun. 2007, 361, 208-213.
22. Hirai, S., Uemura, T., Mizoguchi, N., Lee, J. Y. et al., Diosgenin attenuates inflammatory changes in the interaction between adipocytes and macrophages. Mol. Nutr. Food Res. 2010, 54, 797-804.
23. Liou, C. J., Huang, W. C., Dehydroepiandrosterone suppresses eosinophil infiltration and airway hyperresponsiveness via modulation of chemokines and Th2 cytokines in ovalbumin-sensitized mice. J. Clin. Immunol. 2011, 31, 656-665.
24. Liou, C. J., Huang, W. C., Kuo, M. L., Yang, R. C. et al., Long-term oral administration of Gynostemma pentaphyllum extract attenuates airway inflammation and Th2 cell activities in ovalbumin-sensitized mice. Food Chem. Toxicol. 2010, 48, 2592-2598.
25. Koppen, A., Kalkhoven, E., Brown vs white adipocytes: the PPARgamma coregulator story. FEBS Lett. 2010, 584, 3250-3259.
26. Hegarty, B. D., Turner, N., Cooney, G. J., Kraegen, E. W., Insulin resistance and fuel homeostasis: the role of AMP-activated protein kinase. Acta Physiol. 2009, 196, 129-145.
27. Maeda, N., Hibuse, T., Funahashi, T., Role of aquaporin-7 and aquaporin-9 in glycerol metabolism; involvement in obesity. Handb. Exp. Pharmacol. 2009, 233-249.
28. Lumeng, C. N., Saltiel, A. R., Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 2011, 121, 2111-2117.
29. Achike, F. I., To, N. H., Wang, H., Kwan, C. Y., Obesity, metabolic syndrome, adipocytes and vascular function: a holistic viewpoint. Clin. Exp. Pharmacol. Physiol. 2011, 38, 1-10.
30. McGovern, L., Johnson, J. N., Paulo, R., Hettinger, A. et al., Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J. Clin. Endocrinol. Metab. 2008, 93, 4600-4605.
31. Lafontan, M., Langin, D., Lipolysis and lipid mobilization in human adipose tissue. Prog. Lipid Res. 2009, 48, 275-297.
32. Greenberg, A. S., Obin, M. S., Obesity and the role of adipose tissue in inflammation and metabolism. Am. J. Clin. Nutr. 2006, 83, 461S-465S.
33. Forte, V., Pandey, A., Abdelmessih, R., Forte, G. et al., Obesity, diabetes, the cardiorenal syndrome, and risk for cancer. Cardiorenal. Med. 2012, 2, 143-162.
34. Hsing, A. W., Sakoda, L. C., Chua, S., Jr., Obesity, metabolic syndrome, and prostate cancer. Am. J. Clin. Nutr. 2007, 86, s843-s857.
35. Dixon, A. E., Obesity: changing asthma in the 21st century. Am. J. Respir. Crit. Care Med. 2012, 186, 395-396.
36. Telenga, E. D., Tideman, S. W., Kerstjens, H. A., Hacken, N. H. et al., Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy 2012, 67, 1060-1068.
37. Coppari, R., Bjorbaek, C., Leptin revisited: its mechanism of action and potential for treating diabetes. Nat. Rev. Drug Discov. 2012, 11, 692-708.
38. Myers, M. G., Jr., Heymsfield, S. B., Haft, C., Kahn, B. B. et al., Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 2012, 15, 150-156.
39. Ouchi, N., Parker, J. L., Lugus, J. J., Walsh, K., Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11, 85-97.
40. Klimcakova, E., Kovacikova, M., Stich, V., Langin, D., Adipokines and dietary interventions in human obesity. Obes. Rev. 2010, 11, 446-456.
41. Hassan, M., El Yazidi, C., Malezet-Desmoulins, C., Amiot, M. J. et al., Gene expression profiling of 3T3-L1 adipocytes exposed to phloretin. J. Nutr. Biochem. 2010, 21, 645-652.
42. Ducharme, N. A., Bickel, P. E., Lipid droplets in lipogenesis and lipolysis. Endocrinology 2008, 149, 942-949.
43. Duncan, R. E., Ahmadian, M., Jaworski, K., Sarkadi-Nagy, E. et al., Regulation of lipolysis in adipocytes. Annu. Rev. Nutr. 2007, 27, 79-101.
44. Peng, I. C., Chen, Z., Sun, W., Li, Y. S. et al., Glucagon regulates ACC activity in adipocytes through the CAMKKbeta/AMPK pathway. Am. J. Physiol. Endocrinol. Metab. 2012, 302, E1560-E1568.
45. Wang, Z., Pini, M., Yao, T., Zhou, Z. et al., Homocysteine suppresses lipolysis in adipocytes by activating the AMPK pathway. Am. J. Physiol. Endocrinol. Metab. 2011, 301, E703-E712.
46. Lasa, A., Schweiger, M., Kotzbeck, P., Churruca, I. et al., Resveratrol regulates lipolysis via adipose triglyceride lipase. J. Nutr. Biochem. 2012, 23, 379-384.
47. Gaidhu, M. P., Anthony, N. M., Patel, P., Hawke, T. J. et al., Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am. J. Physiol. Cell Physiol. 2010, 298, C961-C971.
48. Anthony, N. M., Gaidhu, M. P., Ceddia, R. B., Regulation of visceral and subcutaneous adipocyte lipolysis by acute AICAR-induced AMPK activation. Obesity 2009, 17, 1312-1317.
49. Suganami, T., Nishida, J., Ogawa, Y., A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2062-2068.
50. Kim, M. Y., Kim, D. H., Do, M. S., B-cell-activating factor is a regulator of adipokines and a possible mediator between adipocytes and macrophages. Exp. Mol. Med. 2013, 45, e4.
51. Crespy, V., Aprikian, O., Morand, C., Besson, C. et al., Bioavailability of phloretin and phloridzin in rats. J. Nutr. 2001, 131, 3227-3230.
52. Hollman, P. C., de Vries, J. H., van Leeuwen, S. D., Mengelers, M. J. et al., Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr. 1995, 62, 1276-1282.